Revvity, Inc. (RVTY), headquartered in Waltham, Massachusetts, is a leading provider of health sciences solutions, technologies, and diagnostic services. Valued at $11.2 billion by market cap, the company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and other areas.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and RVTY perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the diagnostics & research industry. Revvity’s strengths include diversification, scale, cross-business synergies, brand equity, financial resilience, and technological capabilities. These strengths enable the company to innovate, adapt to market changes, and maintain a competitive edge in the healthcare and diagnostics landscape, driving growth and leadership in the industry.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
Despite its notable strength, RVTY slipped 15.5% from its 52-week high of $118.30, achieved on Jan. 22. Over the past three months, RVTY stock has gained 17.7%, underperforming the Nasdaq Composite’s ($NASX) 20% gains during the same time frame.
www.barchart.com Shares of RVTY rose 3.4% on a YTD basis and climbed 5.9% over the past 52 weeks, underperforming NASX’s YTD gains of 14.1% and 35.7% returns over the last year.
To confirm the bullish trend, RVTY has been trading above its 50-day and 200-day moving averages since early May, experiencing slight fluctuations.
www.barchart.com On May 5, RVTY shares closed up by 6.7% after reporting its Q1 results. Its adjusted EPS came in at $1.06, up 5% year over year. The company’s revenue increased 7% from the year-ago quarter to $711.1 million.
RVTY’s rival, Danaher Corporation (DHR) has lagged behind the stock, with 22.6% losses on a YTD basis and an 8.9% downtick over the past 52 weeks.
Wall Street analysts are reasonably bullish on RVTY’s prospects. The stock has a consensus “Moderate Buy” rating from the 16 analysts covering it, and the mean price target of $113 suggests a potential upside of 13% from current price levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
SpaceX Is Now the Fifth Most Valuable Company on the Planet. How to Play SPCX Stock Here. Plug Power Stock’s Turnaround Is Starting to Look Real Record AI Backlog and Swelling Cash Flows Make HP Enterprise Stock Attractive Strategy Sells Shares to Buy Bitcoin. What This Means for MSTR Stock.